Promotion of nonalcoholic steatohepatitis by RNA N⁶-methyladenosine reader IGF2BP2 in mice

Abstract

Nonalcoholic steatohepatitis (NASH) has emerged as the major cause of end-stage liver diseases. However, an incomplete understanding of its molecular mechanisms severely dampens the development of pharmacotherapies. In the present study, through systematic screening of genome-wide mRNA expression from three mouse models of hepatic inflammation and fibrosis, we identified IGF2BP2, an N⁶-methyladenosine modification reader, as a key regulator that promotes NASH progression in mice. Adenovirus or adeno-associated virus-mediated overexpression of IGF2BP2 could induce liver steatosis, inflammation, and fibrosis in mice, at least in part, by increasing Tab2 mRNA stability. Besides, hepatic overexpression of IGF2BP2 mimicked gene expression profiles and molecular pathways of human NASH livers. Of potential clinical significance, IGF2BP2 expression is significantly upregulated in the livers of NASH patients. Moreover, knockdown of IGF2BP2 substantially alleviated liver injury, inflammation, and fibrosis in diet-induced NASH mice. Taken together, our findings reveal an important role of IGF2BP2 in NASH, which may provide a new therapeutic target for the treatment of NASH.

Keywords

nonalcoholic steatohepatitis / m6A reader / hepatic inflammation / IGF2BP2 / TAB2

References

[1] Younossi Z , Tacke F , Arrese M et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2019; 69: 2672- 82.

[2] Zhou J , Zhou F , Wang W et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology 2020; 71: 1851- 64.

[3] Ferguson D , Finck BN . Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 2021; 17: 484- 95.

[4] Marjot T , Moolla A , Cobbold JF et al. Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management. Endocr Rev 2020; 41: bnz009.

[5] Sheka AC , Adeyi O , Thompson J et al. Nonalcoholic steatohepatitis: a review. JAMA 2020; 323: 1175- 83.

[6] Friedman SL , Neuschwander-Tetri BA , Rinella M et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018; 24: 908- 22.

[7] Loomba R , Friedman SL , Shulman GI . Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021; 184: 2537- 64.

[8] Roundtree IA , Evans ME , Pan T et al. Dynamic RNA modifications in gene expression regulation. Cell 2017; 169: 1187- 200.

[9] Shi H , Wei J , He C . Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol Cell 2019; 74: 640- 50.

[10] Zhao BS , Wang X , Beadell AV et al. m⁶A-dependent maternal mRNA clearance facilitates zebrafish maternal-to-zygotic transition. Nature 2017; 542: 475- 8.

[11] Liu J , Harada BT , He C . Regulation of gene expression by N6-methyladenosine in cancer. Trends Cell Biol 2019; 29: 487- 99.

[12] Zhao X , Yang Y , Sun BF et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell Res 2014; 24: 1403- 19.

[13] Wang Y , Gao M , Zhu F et al. METTL3 is essential for postnatal development of brown adipose tissue and energy expenditure in mice. Nat Commun 2020; 11: 1648.

[14] Wang Y , Sun J , Lin Z et al. m⁶A mRNA methylation controls functional maturation in neonatal murine β-cells. Diabetes 2020; 69: 1708- 22.

[15] De Jesus DF , Zhang Z , Kahraman S et al. m⁶A mRNA methylation regulates human β-cell biology in physiological states and in type 2 diabetes. Nat Metab 2019; 1: 765- 74.

[16] Zhou B , Liu C , Xu L et al. N⁶-methyladenosine reader protein YT521-B homology domain-containing 2 suppresses liver steatosis by regulation of mRNA stability of lipogenic genes. Hepatology 2021; 73: 91- 103.

[17] Guo L , Zhang P , Chen Z et al. Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression. J Clin Invest 2017; 127: 4449- 61.

[18] Clapper JR , Hendricks MD , Gu G et al. Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. Am J Physiol Gastrointest Liver Physiol 2013; 305: G483- 95.

[19] Anakk S , Watanabe M , Ochsner SA et al. Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis. J Clin Invest 2011; 121: 86- 95.

[20] Magee N , Zhang Y . Role of early growth response 1 in liver metabolism and liver cancer. Hepatoma Res 2017; 3: 268- 77.

[21] Zhang Y , Xu N , Xu J et al. E2F1 is a novel fibrogenic gene that regulates cholestatic liver fibrosis through the Egr-1/SHP/EID1 network. Hepatology 2014; 60: 919- 30.

[22] Huang H , Weng H , Sun W et al. Recognition of RNA N⁶-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol 2018; 20: 285- 95.

[23] Zhao Z , Meng J , Su R et al. Epitranscriptomics in liver disease: basic concepts and therapeutic potential. J Hepatol 2020; 73: 664- 79.

[24] Li X , Yuan B , Lu M et al. The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression. Nat Commun 2021; 12: 7213.

[25] Liu J , Ibi D , Taniguchi K et al. Inflammation improves glucose homeostasis through IKKβ-XBP1s interaction. Cell 2016; 167: 1052- 1066.e18.

[26] Kitajima K , Marchadier DH , Miller GC et al. Complete prevention of atherosclerosis in apoE-deficient mice by hepatic human apoE gene transfer with adeno-associated virus serotypes 7 and 8. Arterioscler Thromb Vasc Biol 2006; 26: 1852- 7.

[27] Piao X , Komazawa-Sakon S , Nishina T et al. c-FLIP maintains tissue homeostasis by preventing apoptosis and programmed necrosis. Sci Signal 2012; 5: ra93.

[28] Wang PX , Ji YX , Zhang XJ et al. Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. Nat Med 2017; 23: 439- 49.

[29] Hwang S , He Y , Xiang X et al. Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets. Hepatology 2020; 72: 412- 29.

[30] Lake AD , Novak P , Fisher CD et al. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 2011; 39: 1954- 60.

[31] He Y , Rodrigues RM , Wang X et al. Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis. J Clin Invest 2021; 131: e141513.

[32] Roh YS , Seki E . Chemokines and chemokine receptors in the development of NAFLD. Adv Exp Med Biol 2018; 1061: 45- 53.

[33] Chang B , Xu MJ , Zhou Z et al. Short- or long-term high-fat diet feeding plus acute ethanol binge synergistically induce acute liver injury in mice: an important role for CXCL1. Hepatology 2015; 62: 1070- 85.

[34] Su L , Li N , Tang H et al. Kupffer cell-derived TNF-α promotes hepatocytes to produce CXCL1 and mobilize neutrophils in response to necrotic cells. Cell Death Dis 2018; 9: 323.

[35] Rodrigues RM , He Y , Hwang S et al. E-selectin-dependent inflammation and lipolysis in adipose tissue exacerbate steatosis-to-NASH progression via S100A8/9. Cell Mol Gastroenterol Hepatol 2022; 13: 151- 71.

[36] Ye D , Yang K , Zang S et al. Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2. J Hepatol 2016; 65: 988- 97.

[37] Lee PY , Wang JX , Parisini E et al. Ly6 family proteins in neutrophil biology. J Leukoc Biol 2013; 94: 585- 94.

[38] Bertola A , Park O , Gao B . Chronic plus binge ethanol feeding synergistically induces neutrophil infiltration and liver injury in mice: a critical role for E-selectin. Hepatology 2013; 58: 1814- 23.

[39] Jiang Y , Peng J , Song J et al. Loss of Hilnc prevents diet-induced hepatic steatosis through binding of IGF2BP2. Nat Metab 2021; 3: 1569- 84.

[40] Neuschwander-Tetri BA , Brunt EM , Wehmeier KR et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008- 17.

[41] Gupte AA , Liu JZ , Ren Y et al. Rosiglitazone attenuates ageand diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice. Hepatology 2010; 52: 2001- 11.

[42] Das D , Paul A , Lahiri A et al. Proteasome dysfunction under compromised redox metabolism dictates liver injury in NASH through ASK1/PPARγ binodal complementary modules. Redox Biol 2021; 45: 102043.

[43] Shkoda A , Town JA , Griese J et al. The germinal center kinase TNIK is required for canonical NF-κB and JNK signaling in B-cells by the EBV oncoprotein LMP1 and the CD40 receptor. PLoS Biol 2012; 10: e1001376.

[44] Wang X , Ji Y , Feng P et al. The m⁶A reader IGF2BP2 regulates macrophage phenotypic activation and inflammatory diseases by stabilizing TSC1 and PPARγ. Adv Sci (Weinh) 2021; 8: 2100209.

[45] Xu YR , Lei CQ . TAK1-TABs complex: a central signalosome in inflammatory responses. Front Immunol 2021; 11: 608976.

[46] Liu HB , Muhammad T , Guo Y et al. RNA-Binding protein IGF2BP2/ IMP2 is a critical maternal activator in early zygotic genome activation. Adv Sci (Weinh) 2019; 6: 1900295.

[47] Yin R , Chang J , Li Y et al. Differential m⁶A RNA landscapes across hematopoiesis reveal a role for IGF2BP2 in preserving hematopoietic stem cell function. Cell Stem Cell 2022; 29: 149- 159.e7.

[48] Hwang S , Yun H , Moon S et al. Role of neutrophils in the pathogenesis of nonalcoholic steatohepatitis. Front Endocrinol (Lausanne) 2021; 12: 751802.

[49] Huang C , Liu Q , Tang Q et al. Hepatocyte-specific deletion of Nlrp6 in mice exacerbates the development of non-alcoholic steatohepatitis. Free Radic Biol Med 2021; 169: 110- 21.

[50] Wang JN , Wang F , Ke J et al. Inhibition of METTL3 attenuates renal injury and inflammation by alleviating TAB3 m⁶A modifications via IGF2BP2-dependent mechanisms. Sci Transl Med 2022; 14: eabk2709.

[51] Liu B , Xiang L , Ji J et al. Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2. J Clin Invest 2021; 131: e144801.

[52] Ipsen DH , Lykkesfeldt J , Tveden-Nyborg P . Animal models of fibrosis in nonalcoholic steatohepatitis: do they reflect human disease? Adv Nutr 2020; 11: 1696- 711.

[53] Tsuchida T , Lee YA , Fujiwara N et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol 2018; 69: 385- 95.

[54] Li Y , Xu J , Lu Y et al. DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing. Cell Metab 2021; 33: 2004- 20.e9.

[55] Liu C , Zhou B , Meng M et al. FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease. J Hepatol 2021; 75: 150- 62.

RIGHTS & PERMISSIONS

2022 The Author(s) 2022. Published by Oxford University Press on behalf of Higher Education Press.